[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fLN2e8aesQw8JdLejNbl_mU7sVU-1cakFzP75Uu9V-qY":8,"$fDrfSjHB3eNHJXkkmJo_e4r_1FL6G_-I83JIMVPThdWE":55,"$fKEerIsfjkKrZ84lKYpUzleWa9ocq1lKDOpR3nHJcePM":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},46051,863402,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//0Rvlsm1tdkSbq5L99bjhchaojzwJ5kCw.png","华晓萍","浙江大学医学院附属妇产科医院","妇科","主治医师",94,0,"卵巢癌IVB期相关药品的安全用药全指南","","https://ystcdn.venuertc.com/venue/AI/887b516b-8d33-45b0-937a-d8d15c38cd3e.jpg","\u003Cdiv class=\"ovarian-drug-material\">\n  \u003Cdiv class=\"ovarian-drug-title\" id=\"material_title\">\n    \u003Ch1 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">卵巢癌IVB期相关药品的安全用药全指南\u003C/h1>\n    \u003Cdiv class=\"ovarian-drug-title-underline\">\u003C/div>\n  \u003C/div>\n  \u003Cdiv class=\"ovarian-drug-intro\">\n    说到卵巢癌用药，最常听见的就是紫杉醇和卡铂，这两种化疗药联合应用已成为治疗的重要方式。不过，用药过程中的每一个细节都可能影响疗效和安全。本文将帮您梳理紫杉醇、卡铂等药品使用时最值得注意的\u003Cstrong>7大关键细节\u003C/strong>，让大家能真正做到明白用药、安心用药。\n  \u003C/div>\n\n  \u003C!-- Section 1: 药品分类与核心成分 -->\n  \u003Cdiv class=\"ovarian-section ovarian-bg-1\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">1️⃣ 药品分类与主要成分简介\u003C/h2>\n    \u003Cdiv class=\"ovarian-section-block\">\n      \u003Cp>\n        实际用药时，卵巢癌IVB期常用于化疗的核心药物主要有：\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-name\">紫杉醇（Paclitaxel）\u003C/span>：属于植物来源的抗肿瘤药，作用于细胞有丝分裂过程；\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-name\">卡铂（Carboplatin）\u003C/span>：铂类化疗药，通过影响细胞DNA结构起效。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        辅助用药如氨磷汀、地塞米松、兰索拉唑等，主要用于缓解副作用或保护其他脏器，均有各自的用药讲究。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- Section 2: 作⽤机制简明解读 -->\n  \u003Cdiv class=\"ovarian-section ovarian-bg-2\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">2️⃣ 药理作用——如何起效？\u003C/h2>\n    \u003Cdiv class=\"ovarian-section-block\">\n      \u003Cp>\n        \u003Cspan class=\"ovarian-drug-name\">紫杉醇\u003C/span>\n        通过稳定细胞微管，阻止肿瘤细胞分裂，最终导致细胞死亡。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"ovarian-drug-name\">卡铂\u003C/span>\n        则会与细胞DNA交联，破坏基因复制和转录过程，使细胞无法正常分裂。\n      \u003C/p>\n      \u003Cp>\n        二者联合用药，能从不同环节增强抗瘤效果，是目前国际公认的化疗标准方案之一（McGuire et al., 1996）。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- Section 3: 用药方法与正确操作要点 -->\n  \u003Cdiv class=\"ovarian-section ovarian-bg-3\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">3️⃣ 给药时间、方法与操作技巧\u003C/h2>\n    \u003Cdiv class=\"ovarian-section-block\">\n      \u003Cp>\n        化疗药多为\u003Cstrong>静脉输注\u003C/strong>。不同药物有严格的给药要求，请注意下述操作细节：\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>紫杉醇\u003C/strong>：常用三小时静滴方式，应用前需用抗过敏药物预处理（如地塞米松），以减少过敏反应风险。\u003C/li>\n        \u003Cli>\n          \u003Cstrong>卡铂\u003C/strong>：同样为静脉滴注，通常与紫杉醇分开序贯给药。\u003C/li>\n        \u003Cli>\n          输注过程中应全程监测，出现红肿、疼痛要及时报告医护人员。\u003C/li>\n        \u003Cli>\n          每次化疗前建议检查白细胞、肝肾功能，避免药物在体内蓄积或引发异常反应。\u003C/li>\n      \u003C/ul>\n      \u003Cp>生活经验：有位51岁患者，每次输完药当天多喝温水，能缓解部分不适感，这也是辅助手段之一。\u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- Section 4: 剂量规格、漏服与过量应对 -->\n  \u003Cdiv class=\"ovarian-section ovarian-bg-4\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">4️⃣ 剂量规格、漏服及过量用药怎么办？\u003C/h2>\n    \u003Cdiv class=\"ovarian-section-block\">\n      \u003Cp>\n        \u003Cstrong>剂量规格\u003C/strong>要求医生根据体表面积、个体耐受性严格计算。患者不得随意调整剂量，两种药品均为\u003Cstrong>周期性用药\u003C/strong>，切勿自行加用、延迟或中断。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>如一次漏服（实际为化疗未按计划进行），应立即联系专科医生，切勿自行补用。\u003C/li>\n        \u003Cli>过量输注后，可能出现严重副作用，包括骨髓抑制，处理上以支持治疗为主，及时就医是唯一选择。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        科学提示：化疗间隔一般为21天，具体安排请遵医嘱，强化周期管理更安全。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- Section 5: 典型不良反应与应对措施 -->\n  \u003Cdiv class=\"ovarian-section ovarian-bg-5\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">5️⃣ 常见不良反应与应对策略 🚦\u003C/h2>\n    \u003Cdiv class=\"ovarian-section-block\">\n      \u003Cp>\n        化疗药物虽有效，但副作用不可小觑。\u003Cbr>\n        \u003Cstrong>常见不良反应包括：\u003C/strong>\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>紫杉醇：过敏反应（皮疹、呼吸困难）、神经毒性（肢端麻木）、脱发；\n        \u003C/li>\u003Cli>卡铂：骨髓抑制（白细胞、血小板下降）、恶心呕吐、肾功能影响。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        正确做法：\n        \u003C/p>\u003Cul>\n          \u003Cli>用药当天及之后数天关注体温，发现异常或感染迹象要及时告诉医生；\u003C/li>\n          \u003Cli>脱发、麻木、乏力等表现通常为可逆性副作用，建议与主治医师沟通调整用药方案；\u003C/li>\n          \u003Cli>伴用地塞米松、氨磷汀主要用于降低过敏反应和神经损伤发生率。\u003C/li>\n        \u003C/ul>\n      \u003Cp>\u003C/p>\n      \u003Cp>\n        临床数据：\u003Cspan class=\"ovarian-stat\">紫杉醇相关过敏反应发生率1.5%-3%\u003C/span>，神经毒性发生率可达60%（Rowinsky et al., 1993）。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- Section 6: 药物相互作用与禁止同用药品 -->\n  \u003Cdiv class=\"ovarian-section ovarian-bg-6\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">6️⃣ 药物相互作用与配伍禁忌 ❗\u003C/h2>\n    \u003Cdiv class=\"ovarian-section-block\">\n      \u003Cp>化疗期间常合并辅助药，药物相互作用须警惕：\u003C/p>\n      \u003Cul>\n        \u003Cli>紫杉醇不能与阿司匹林、华法林等出血风险高的药物合用。\u003C/li>\n        \u003Cli>卡铂如联用有肾毒性的药，如氨基糖苷类抗生素，肾损伤风险升高。\u003C/li>\n        \u003Cli>强效CYP3A4诱导剂或抑制剂（如酮康唑、利福平）会明显影响紫杉醇代谢，须查明全部用药史后再使用。\u003C/li>\n        \u003Cli>配伍时必须用专用溶剂，不能与其他药物同瓶混合。\u003C/li>\n      \u003C/ul>\n      \u003Cp>正确做法：\u003C/p>\n      \u003Cul>\n        \u003Cli>使用前主动向医生报告正在服用的全部药物，包括中草药、保健品；\u003C/li>\n        \u003Cli>用药中如发现不明原因的异常症状，及时停药并联系医生。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- Section 7: 储存条件、有效期与安全处理 -->\n  \u003Cdiv class=\"ovarian-section ovarian-bg-7\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">7️⃣ 储存要求、有效期及处理🔐\u003C/h2>\n    \u003Cdiv class=\"ovarian-section-block\">\n      \u003Cp>\n        化疗药剂由专业药房提供，一般现场配制、用完即弃，但日常辅助口服药需注意：\u003C/p>\n      \u003Cul>\n        \u003Cli>放于阴凉干燥处，避光储存，\u003Cstrong>温度不超过25°C\u003C/strong>，湿度适中。\u003C/li>\n        \u003Cli>如发现药品变色、混浊、结块，不可继续使用，应主动交回医院或药房妥善处理。\u003C/li>\n        \u003Cli>定期核查药品有效期，过期药品绝不可自行处理或投放生活垃圾。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        特殊提示：化疗药品接触皮肤、眼睛时需立即用大量清水冲洗，并及时就医。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- Section 8: 特殊人群用药与个体差异 -->\n  \u003Cdiv class=\"ovarian-section ovarian-bg-8\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">8️⃣ 特殊人群用药须知 👩‍👧‍👦\u003C/h2>\n    \u003Cdiv class=\"ovarian-section-block\">\n      \u003Cul>\n        \u003Cli>\u003Cstrong>高龄、肝肾功能异常\u003C/strong>者：剂量需调整，用药期间重点监控肝肾功能及造血系统。\u003C/li>\n        \u003Cli>\u003Cstrong>孕妇、哺乳期女性\u003C/strong>：本类药品\u003Cspan class=\"ovarian-danger\">孕期严禁\u003C/span>，哺乳期亦不可用。怀孕计划要提前半年停药。\u003C/li>\n        \u003Cli>\u003Cstrong>青少年\u003C/strong>使用本类药物时需有严格医学评估。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        正确做法：如有高血压等基础疾病，治疗前需告知医生，由专业人员评估是否能耐受。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- Section 9: 辅助用药与联合给药注意事项 -->\n  \u003Cdiv class=\"ovarian-section ovarian-bg-9\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">9️⃣ 辅助药品使用小贴士 💊\u003C/h2>\n    \u003Cdiv class=\"ovarian-section-block\">\n      \u003Cp>\n        化疗期间，常需加用抗过敏、护胃等药品：\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>地塞米松：通常于化疗前30分钟静注，降低过敏反应和恶心呕吐风险。\u003C/li>\n        \u003Cli>氨磷汀：用于降低铂类药物引起的肾毒性及神经毒性。\u003C/li>\n        \u003Cli>兰索拉唑：抑酸护胃药，减少化疗期间胃肠道不适。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        用药过程中，需严格按医嘱执行剂量与时间安排，如出现皮肤瘙痒、口腔异味等新症状，请主动报告医护人员。\n      \u003C/p>\n      \u003Cp>\n        一位没有药物过敏史的51岁女性，接受三次紫杉醇联合卡铂化疗后，仅出现轻微脱发和口腔不适，经调整药物搭配后顺利度过治疗周期。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- Section 10: 全面总结与安全用药再强调 -->\n  \u003Cdiv class=\"ovarian-section ovarian-bg-10\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">🔟 全面总结与安全用药提醒 📝\u003C/h2>\n    \u003Cdiv class=\"ovarian-section-block\">\n      \u003Cp>\n        回顾以上内容，紫杉醇与卡铂的顺利应用，离不开按计划给药、科学监测副作用、预防药物相互作用及规范储存等诸多细节。每一项都直接关乎治疗效果和用药安全。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>务必遵循专业医生的用药安排，切勿自行改药、停药、换药。\u003C/li>\n        \u003Cli>出现异常反应，宁可\"小题大做\"及时就医，也不可掉以轻心。\u003C/li>\n        \u003Cli>不要疏忽药品的有效期与储存条件，日常辅助药亦需关注。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        合理用药，既是积极的治疗保障，也是每一位患者和家属应承担的责任。遇到任何用药疑问，主动与医护人员沟通始终是最安全的选择。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 参考文献 -->\n  \u003Cdiv class=\"ovarian-section ovarian-bg-ref\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">📚 主要参考文献\u003C/h2>\n    \u003Cdiv class=\"ovarian-section-block\">\n      \u003Cul>\n        \u003Cli>\n          McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., ... & Roth, L. M. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. \u003Ci>New England Journal of Medicine, 334\u003C/i>(1), 1-6. \n        \u003C/li>\n        \u003Cli>\n          Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1993). Taxol: a novel investigational antimicrotubule agent. \u003Ci>Journal of Clinical Oncology, 10\u003C/i>(3), 173-191.\n        \u003C/li>\n        \u003Cli>\n          Calvert, A. H., Newell, D. R., Gumbrell, L. A., & Harrap, K. R. (1989). Carboplatin dosage: prospective evaluation of a simple formula based on renal function. \u003Ci>Journal of Clinical Oncology, 7\u003C/i>(11), 1748-1756.\n        \u003C/li>\n        \u003Cli>\n          Bookman, M. A., Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M., ... & Ozols, R. F. (2009). Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. \u003Ci>Journal of Clinical Oncology, 27\u003C/i>(9), 1419-1425.\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\u003Cstyle>\n.ovarian-drug-material {\n  max-width:800px;\n  margin:35px auto 30px auto;\n  padding:18px 15px 32px 15px;\n  background:#fafbfa;\n  border-radius:14px;\n  box-shadow:0px 4px 18px rgba(119,125,147,0.13);\n  font-family:'PingFang SC','Segoe UI',Arial,sans-serif;\n  color:#23262e;\n}\n.ovarian-drug-title {\n  text-align:center;\n  margin-top:5px;\n  margin-bottom:11px;\n  background:linear-gradient(90deg,#f1f7fa 12%,#dbeff7 100%);\n  border-radius:10px 10px 0 0;\n  padding:28px 5px 18px 5px;\n  box-shadow:0 8px 20px 0 rgba(187,207,235,0.12);\n  position:relative;\n}\n.ovarian-drug-title h1 {\n  margin:0;\n  font-size:29px;\n  letter-spacing:1.2px;\n  font-weight:600;\n  color:#04466f;\n}\n.ovarian-drug-title-underline {\n  width:52px;height:6px;\n  background:linear-gradient(90deg,#52b2e1 20%,#afd3e9 96%);\n  border-radius: 3px;\n  margin:13px auto 0 auto;\n}\n.ovarian-drug-intro {\n  font-size:16px;\n  color:#2a4663;\n  background:linear-gradient(90deg, #f9fafe 50%, #f4faff 100%);\n  padding:18px 18px 16px 18px;\n  border-radius:6px;\n  margin-bottom:17px;\n  margin-top:13px;\n  box-shadow:0 4px 6px rgba(186,206,227,0.06);\n}\n.ovarian-section {\n  margin-top:32px;\n  margin-bottom:0;\n  border-radius:13px;\n  box-shadow:0 3px 14px rgba(180,220,235,0.09);\n  padding:0;\n}\n.ovarian-section h2 {\n  margin:0;\n  font-size:22px;\n  background:none;\n  color:#1371a8;\n  font-weight:600;\n  border-radius:13px 13px 0 0;\n  padding:21px 18px 18px 18px;\n  position:relative;\n  letter-spacing:0.9px;\n  box-shadow:0 1px 2px 0 rgba(204,225,244,0.06);\n  /* 背景随节变化 */\n}\n.ovarian-section-block {\n  background:rgba(255,255,255,0.96);\n  padding:15px 22px 18px 22px;\n  font-size:16px;\n  line-height:1.74;\n  color:#345870;\n  border-radius:0 0 13px 13px;\n}\n.ovarian-section-block ul {\n  padding:0 0 0 18px;\n  margin:10px 0 11px 0;\n}\n.ovarian-section-block li {\n  margin-bottom:6px;\n  line-height:1.68;\n}\n.ovarian-drug-name {\n  color:#ba376b;\n  font-weight:600;\n}\n.ovarian-stat {\n  color:#397e6d;\n  font-size:15px;\n  font-weight:500;\n}\n.ovarian-danger {\n  color:#c83636;\n  font-weight:600;\n  letter-spacing:0.5px;\n}\n.ovarian-bg-1 h2 {background:linear-gradient(90deg,#e5f2fd 0%, #edf7fc 75%);}\n.ovarian-bg-2 h2 {background:linear-gradient(90deg,#e1f2ef 0%, #f3faf9 60%);}\n.ovarian-bg-3 h2 {background:linear-gradient(90deg,#f3f4fa 12%, #e2efe9 90%);}\n.ovarian-bg-4 h2 {background:linear-gradient(90deg,#f7f3f7 0%, #eaf4ef 70%);}\n.ovarian-bg-5 h2 {background:linear-gradient(90deg,#e2f2fb 0%, #f6fafe 80%);}\n.ovarian-bg-6 h2 {background:linear-gradient(90deg,#efe4f7 0%, #e5f2fa 80%);}\n.ovarian-bg-7 h2 {background:linear-gradient(90deg,#f6faeb 0%, #e8f4df 70%);}\n.ovarian-bg-8 h2 {background:linear-gradient(90deg,#e2edf8 0%, #f6fafc 90%);}\n.ovarian-bg-9 h2 {background:linear-gradient(90deg,#f4f9ef 0%, #e8f5e9 60%);}\n.ovarian-bg-10 h2 {background:linear-gradient(90deg,#eaf7fe 0%, #f7faff 100%);}\n.ovarian-bg-ref h2 {\n  background:linear-gradient(90deg,#f5f7fd 0%, #f9fafc 100%);\n  color:#6e7687;\n  font-size:20px;\n  padding-left:20px;\n}\n\n/* 响应式设计 */\n@media only screen and (max-width:900px) {\n  .ovarian-drug-material {max-width:98vw;padding:10px 3px;}\n  .ovarian-section-block {padding-left:7px;padding-right:7px;}\n}\n@media only screen and (max-width:600px) {\n  .ovarian-drug-title h1 {font-size:19px;}\n  .ovarian-section h2 {font-size:15px;padding-left:10px;}\n}\n\u003C/style>\n\n","\u003Cdiv class=\"ovarian-drug-material\">\n  \u003Cdiv class=\"ovarian-drug-title\" id=\"material_title\">\n    \u003Ch1 s",521,"2025-07-03 18:05:41","卵巢癌, 紫杉醇, 卡铂, 化疗药物, 用药安全","了解卵巢癌IVB期常用化疗药物紫杉醇与卡铂的安全用药指南，包括给药方法、不良反应和药物相互作用，助您安心治疗。","2025-07-06 06:12:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]